State Street
FLGT icon

State Street’s Fulgent Genetics FLGT Stock Holding History

State Street’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.2M Sell
498,673
-30,726
-6% -$521K ﹤0.01% 2694
2026
Q1 		$8.42M Buy
529,399
+35,735
+7% +$776K ﹤0.01% 2704
2025
Q4 		$13M Sell
493,664
-8,332
-2% -$216K ﹤0.01% 2497
2025
Q3 		$11.3M Sell
501,996
-11,801
-2% -$243K ﹤0.01% 2571
2025
Q2 		$10.2M Buy
513,797
+7,012
+1% +$137K ﹤0.01% 2592
2025
Q1 		$8.56M Sell
506,785
-312,637
-38% -$5.32M ﹤0.01% 2628
2024
Q4 		$15.1M Buy
819,422
+25,877
+3% +$505K ﹤0.01% 2379
2024
Q3 		$17.2M Buy
793,545
+10,868
+1% +$243K ﹤0.01% 2302
2024
Q2 		$15.4M Sell
782,677
-41,800
-5% -$873K ﹤0.01% 2303
2024
Q1 		$17.9M Buy
824,477
+11,545
+1% +$287K ﹤0.01% 2243
2023
Q4 		$23.5M Buy
812,932
+40,856
+5% +$1.09M ﹤0.01% 2123
2023
Q3 		$20.6M Buy
772,076
+15,915
+2% +$543K ﹤0.01% 2163
2023
Q2 		$28M Sell
756,161
-42,920
-5% -$1.5M ﹤0.01% 2025
2023
Q1 		$24.9M Sell
799,081
-6,994
-0.9% -$225K ﹤0.01% 2079
2022
Q4 		$24M Buy
806,075
+49,718
+7% +$1.78M ﹤0.01% 2108
2022
Q3 		$28.8M Buy
756,357
+38,121
+5% +$1.91M ﹤0.01% 1965
2022
Q2 		$39.2M Buy
718,236
+22,153
+3% +$1.22M ﹤0.01% 1812
2022
Q1 		$43.4M Buy
696,083
+70,764
+11% +$4.66M ﹤0.01% 1858
2021
Q4 		$62.9M Buy
625,319
+3,768
+0.6% +$331K ﹤0.01% 1657
2021
Q3 		$55.9M Buy
621,551
+12,372
+2% +$1.12M ﹤0.01% 1730
2021
Q2 		$56.2M Buy
609,179
+150,062
+33% +$12M ﹤0.01% 1760
2021
Q1 		$44.4M Buy
459,117
+47,260
+11% +$4.88M ﹤0.01% 1823
2020
Q4 		$21.5M Buy
411,857
+146,193
+55% +$6.11M ﹤0.01% 2208
2020
Q3 		$10.6M Buy
265,664
+130,881
+97% +$4.1M ﹤0.01% 2408
2020
Q2 		$2.16M Buy
+134,783
New +$2.06M ﹤0.01% 3151
2017
Q2 		– Sell
-50,076
Closed -$549K – 3714
2017
Q1 		$549K Buy
+50,076
New +$592K ﹤0.01% 3368

Other funds holding FLGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
DC
Diametric Capital Boston, Massachusetts $948M AUM 47.49% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return

State Street's FLGT Position: Q2 2026 in Review

State Street reduced its Fulgent Genetics (FLGT) stake by 5.8% in Q2 2026, selling an estimated $521K and leaving 498,673 shares worth $10.2M. The position accounts for ﹤0.01% of the portfolio, ranked #2694.

State Street first reported a position in FLGT in Q1 2017 and has held it in 26 quarters since. The position peaked at $62.9M in Q4 2021. 141 funds tracked by Wall St. Rank hold FLGT as of Q2 2026.

  • State Street held 498,673 shares of Fulgent Genetics worth $10.2M as of Q2 2026.
  • State Street sold 30,726 Fulgent Genetics shares in Q2 2026, an estimated $521K.
  • Fulgent Genetics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #2694 holding.
  • State Street first reported a position in Fulgent Genetics in Q1 2017 and has held it in 26 quarters since.
  • State Street's Fulgent Genetics position peaked at $62.9M in Q4 2021.
  • 141 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.